Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis

Executive Summary

Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.

You may also be interested in...



10 Triumphant Drug Launches Of The Decade

The view from 2020: Scrip looks back at the most successful commercial launches of the decade.

Tecfidera Stands Out From The Pack Of 2013 Drug Launches

Biogen Idec’s Tecfidera, on track to generate more than $1 billion in sales its first 12 months on the market, was the exceptional drug launch of 2013, in a year that included few breakout stars.

Business News, In Brief

Companies discuss their plans to move pipelines forward as the third quarter wraps up and they prepare for new launches and new indications in the coming year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS053972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel